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Commentary
Are the Italian ethics committees  
ready for Europe?
Carlo Petrini
Unità di Bioetica, Istituto Superiore di Sanità, Rome, Italy
The Law of 8 November 2012 [1] required each Ital-
ian region to reorganize its ethics committees by 30 
June 2013 in line with criteria laid down in the relevant 
decree that was subsequently published on 8 February 
2013 under the title “Criteria for the composition and 
functioning of ethics committees” [2].
The implementation of the Law, which makes the Re-
gional Authorities responsible for establishing the local 
ethics committees in their area, involved a significant 
reduction in the number of local ethics committees in 
Italy [3]: from 243 committees in 2012 to just 93 in 
2014. In the meantime, mergers have taken place in 
some regions and the number of local ethics commit-
tees currently stands at 72. 
The following year, the European Union adopted 
and implemented Regulation (EU) 536/2014 of the 
European Parliament and of the Council of 16th April 
2014 on clinical trials on medicinal products for hu-
man use, repealing Directive 2001/20/EC [4]. The 
Regulation establishes a new set of harmonised rules 
that all member states are required to apply in all clini-
cal trials performed throughout the European Union 
(EU).
Pending the full implementation of the Regula-
tion (which, as established in article 99, will occur six 
months after the publication in the Official Journal of the 
European Union of a notice regarding the full function-
ality of a portal and a database containing the data and 
the information submitted in accordance with the same 
Regulation), the Italian Government passed Law no. 3 
of 11 January 2018 [5], which introduces, in articles 1 
and 2, important changes in the procedures for the au-
thorisation of clinical trials and regarding the organiza-
tion and operation of ethics committees.
The Law also envisages a further reduction in the 
number of local ethics committees: a Ministerial De-
cree (replacing regional provisions) will be issued es-
tablishing 40 local ethics committees and 3 committees 
of facilities with national competence. As regards the 
establishment of the local committees, there must be 
at least one for each region (article 2, subsection 7) [5]. 
One particularly important provision of the law is the 
establishment, within Agenzia Italiana del Farmaco 
(Italian Medicines Agency, AIFA), of the “National 
Centre for the Coordination of Regional Ethics Com-
mittees for Clinical Trials of Medicines and Medical 
Devices for Human Use” (in Italian: Centro di coor-
dinamento nazionale dei comitati etici territoriali per le 
sperimentazioni cliniche sui medicinali per uso umano 
e sui dispositivi medici) [5]. 
According to the Law, the National Centre:
• is responsible for the coordination, guidance and 
monitoring of the assessment of the ethical aspects 
concerning clinical trials on medicinal products for 
human use performed by the local ethics committees;
• intervenes, when requested to do so by the individual 
local ethics committees, to provide support and ad-
vice;
• may be involved in the procedures regarding the eval-
uation of clinical studies requiring review following 
adverse event reports;
• monitors the activities performed by the local ethics 
committees and reports breaches of the terms set forth 
in the aforesaid Regulation (EU) no. 536/2014 [4];
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• in cases of inertia or, in any case, cases of failure to 
comply with the terms set forth in said regulation, 
it suggests that the Ministry of Health suppress the 
non-compliant local ethics committee;
• provides general guidance in the interest of procedur-
al uniformity and compliance with the terms for the 
assessment of clinical trials on medical devices and 
medicines for human use.
The reduction in the number of ethics committees 
and the establishment of the National Centre are the 
result of a lively debate [6] regarding the organization 
of ethics committees that, in Italy and the whole Euro-
pean Union, followed the adoption of Regulation (EU) 
536/2014 [4], during which a number of different pro-
posals emerged [7, 8] (including that of centralising the 
assessment of all the clinical trials conducted in Italy 
with a single committee for the whole of the country). 
The ethics committees have high expectations from 
the National Centre: it is hoped that it will put an end 
to the fragmentation and lack of homogeneity that cur-
rently characterise the country’s ethics committees. 
As specified in article 2, subsection 4 of the Law [5], 
the fifteen members of the National Centre were ap-
pointed by specific Ministry of Health Decree on 19 
April 2018 [9]. According to the same Law, of the Na-
tional Centre members appointed by the Ministry, two 
were put forward by the Conference of Regional and 
Autonomous Provincial Authorities and three were put 
forward by the most representative patient advocacy 
groups (the Law mentions “at least two”). The remain-
ing members are university professors and directors 
working for national health institutions (including my-
self*). According to the Law, meetings of the National 
Centre may be attended by the Chairs of the National 
Bioethics Committee, National Committee for Bios-
ecurity, Biotechnology and Life Sciences and the Ital-
ian National Institute of Health. The implementation 
Decree appointing the fifteen members increased the 
three participants to four (with the addition of the Gen-
eral Manager of the AIFA) [9].
The commitment must be, first and foremost, to per-
form at least those duties that are attributed to the Na-
tion Centre by law [5]. However, hopefully, it also be 
to reorganize or reform many other areas that require 
national intervention. The most urgent of these are: 
• the review of the procedures for the evaluation of ob-
servational studies (starting from the very definition 
of “observational study” [10]);
• the review of regulations governing “no profit” [11] 
studies;
• the harmonisation of the procedures for the assess-
ment of studies other than clinical trials (studies in-
volving biological samples, epidemiological studies, 
etc.);
• the organization and promotion of clinical ethics 
committees providing guidance on clinical cases in 
medical facilities, rather than being dedicated to the 
assessment of clinical trials. 
Accepted on 26 September 2018.
*I declined the post of President of the National Centre and assumed 
the role of Vice President. 
REFERENCES
1. Parlamento Italiano. Legge 8 novembre 2012, n. 189. 
Conversione in legge, con modificazioni, del decreto-
legge 13 settembre 2012, n. 158, recante disposizioni 
urgenti per promuovere lo sviluppo del Paese mediante 
un più alto livello di tutela della salute. Gazzetta Ufficiale 
della Repubblica Italiana – Serie generale 10 novembre 
2012;263(Suppl. Ord. 201):1-64.
2. Ministero della Salute. Decreto 8 febbraio 2013. Crite-
ri per la composizione e il funzionamento dei comitati 
etici. Gazzetta Ufficiale della Repubblica Italiana – Serie 
generale 24 aprile 2013;96:12-21.
3. Petrini C. Some comments on the new regulations gov-
erning Ethics Committees in Italy. Ann Ist Super Sanità. 
2014;50(2):160-2.
4. European Parliament, Council of the European Union. 
Regulation (EU) 536/2014 of the European Parliament 
and of the Council of 16 April 2014 on clinical trials on 
medicinal products for human use, and repealing Direc-
tive 2001/20/EC. Official Journal of the European Union 
27 May 2014;L158:1-76.
5. Parlamento italiano. Legge 11 gennaio 2018 n. 3. Delega 
al Governo in materia di sperimentazione clinica di me-
dicinali nonché disposizioni per il riordino delle profes-
sioni sanitarie e per la dirigenza sanitaria del Ministero 
della salute. Gazzetta Ufficiale della Repubblica Italiana 
– Serie generale 31 gennaio 2018;25:10-39.
6. Petrini C. What is the role of ethics committees after Reg-
ulation (EU) 536/2014? J Med Ethics. 2016;42(3):186-8.
7. Petrini C, Garattini S. Trials, Regulation and tribulations. 
Eur J Clin Pharmacol. 2016:72(4):303-5.
8. Petrini C. Regulation (EU) No 536/2014 on clinical trials 
on medicinal products for human use: an overview. An-
nali Ist Super Sanità. 2014;50(4):317-21.
9. Ministero della Salute. Comunicato. Costituzione del 
Centro di coordinamento nazionale dei comitati etici 
territoriali per le sperimentazioni cliniche sui medicinali 
per uso umano e sui dispositivi medici. Gazzetta Uffi-
ciale della Repubblica Italiana – Serie generale 10 maggio 
2018;107:63.
10. Agenzia Italiana del Farmaco. Determinazione 20 marzo 
2008. Linee guida per la classificazione e conduzione 
degli studi osservazionali sui farmaci. Gazzetta Uffici-
ale della Repubblica Italiana - Serie generale 31 marzo 
2008;76:68-74.
11. Ministero della Salute. Decreto 17 dicembre 2004. 
Prescrizioni e condizioni di carattere generale, relative 
all’esecuzione delle sperimentazioni cliniche dei medic-
inali, con particolare riferimento a quelle ai fini di mi-
glioramento della pratica clinica, quale parte integrante 
dell’assistenza sanitaria. Gazzetta Ufficiale della Repub-
blica Italiana – Serie Generale 22 febbraio 2015;43:26-
32.
